Cellestia Biotech
Basel, Switzerland ยท Sport and Recreation
This profile has not been verified by the business owner.
Information may be incomplete or outdated.
#Biopharma
#Oncology
#Precision Medicine
#Small Molecules
#Targeted Therapy
#Biotech
#Cancer Therapy
#Transcription Factors
#Autoimmune Disorders
#Inflammatory Disorders
Overview
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.
Contact Details
info@cellestia.com
Basel, Switzerland
Founded
2014
Employees
10-20
Keywords
#Biopharma
#Oncology
#Precision Medicine
#Small Molecules
#Targeted Therapy
#Biotech
#Cancer Therapy
#Transcription Factors
#Autoimmune Disorders
#Inflammatory Disorders
Companies teams usually look at after Cellestia Biotech
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.